Abstract Type : Poster
Presentation No. : PAK 022

High calcium-phosphorus product level increases the risk of acute kidney injury, end-stage renal disease, and mortality in hospitalized patients

Hongran Moon, Dong Ki Kim, Ho Jun Jin, Kwon Wook Joo, Yon Su Kim, Ki Young Na, Sejoong Kim, Seung Seok Han
Department of Internal Medicine, Seoul National University Hospital, Korea, Republic of

Objectives:
Calcium-phosphorus (Ca-P) product level is an important concern in chronic kidney disease patients, regarding vascular calcification and mineral bone disorder. However, the clinical implications of Ca-P production in the risk of acute kidney injury (AKI), end-stage renal disease (ESRD), and mortality after hospitalization remain unresolved.

Methods:
A total of 16,757 patients (aged ≥18 years) were retrospectively reviewed from a tertiary referral center who admitted during 2013 year. Patients were categorized into 4 groups by the quartiles of Ca-P product (Ca × P) at the time of admission. The odds ratios (ORs) for AKI and ESRD and hazard ratios (HRs) for all-cause mortality were calculated after adjusting multiple covariates.

Results: The ranges of Ca-P product levels were < 24.9 in the 1st quartile, 24.9–29.5 in the 2nd quartile, 29.6–34.0 in the 3rd quartile, and > 34.0 in the 4th quartile. AKI developed in 2,010 patients (12.0%). The 4th quartile group had a higher OR of AKI [1.40 (1.182-1.651)] than the 1st quartile group. The recovery rate from AKI was lower in the 4th quartile than in the 1st quartile with an OR of 0.74 (0.584-0.927). Furthermore, the 3rd and 4th quartile groups had a risk of ESRD compared to the 1st quartile, with ORs of 2.43 (1.415-4.170) and 2.59 (1.543-4.347), respectively. During the median follow-up period of 3.6 years (maximum 5 years), 284 patients (1.7%) died. The 4th quartile group had a higher HR of mortality [2.64 (1.870-3.737)] than the 1st quartile group.

Conclusions:
High Ca-P product level is related with the risk of AKI, ESRD, and mortality. Accordingly, it may be needed to monitor Ca-P product levels in the hospitalized patients in addition to the chronic kidney disease patients.